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Intravesical immunotherapy with bacille Calmette-Guérin (BCG) vaccine is the
main treatment for non-muscle-invasive bladder cancer (NMIBC), with proven
effects on reducing recurrence, progression, and death from NMIBC. However, it is
not effective in all patients, and recurrence after adequate BCG therapy can
frequently lead to progression to more life-threatening disease. This point-coun-
terpoint review considers how to treat a healthy 60-yr-old patient with T1 high-
grade NMIBC fitting the new definition of BCG-unresponsive disease, that is,
persistent high-grade disease at 6–12 mo, despite an adequate course of induction
and maintenance with BCG.
Patient summary: When T1 high-grade non-muscle-invasive bladder cancer is per-
sistent or recurs shortly after a full course of bacille Calmette-Guérin (BCG) plus
maintenance, further BCG is not likely to work; this meets the new definition of a “BCG
unresponsive” disease. For this situation, the safest (curative) option is removal of the
bladder. If that is not an accepted alternative, then a clinical trial or combination
intravesical chemotherapy or hyperchemotherapy may be another option.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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The patient is a healthy 60-yr-old man who presented with
gross hematuria. Cystoscopy showed an accessible tumor
on the right wall, and transurethral resection of the bladder
tumor (TURBT) with blue light revealed a T1 high-grade,
pure urothelial carcinoma with muscle present but not
involved. This was confirmed in a second opinion from
another pathologist. A planned repeat TURBT at 4 wk
revealed a small focus of cancer in situ (CIS), with nohttps://doi.org/10.1016/j.euo.2019.06.013
2588-9311/© 2019 The Authors. Published by Elsevier B.V. on behalf of Euro
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncpapillary involvement. Imaging was negative for upper tract
or metastatic disease.
After an informed discussion, the patient elected to
receive 6-wk induction of intravesical bacille Calmette-
Guérin (BCG), which was tolerated fairly well. His 3-mo
cystoscopy and cytology were negative.
Induction was followed by 3-wk maintenance with BCG.
At the 6th-month evaluation, a small (0.5 cm) lesion was
noted at the dome, distant from the original tumor. TURBT
showed CIS plus a Ta high-grade tumor. The rest of thepean Association of Urology. This is an open access article
-nd/4.0/).
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results of random biopsies were negative as well.
This patient fits the new definition of BCG-unresponsive
disease by virtue of having persistent high-grade disease at
6 mo, despite induction and maintenance with BCG.
So the question is, what do you do now?
2. Option A: Conservative treatment in high-risk
BCG-unresponsive non-muscle-invasive bladder cancer
This clinical case pertains to a high-risk non-muscle-invasive
bladder cancer (NMIBC) (originally a solitary T1G3 with CIS)
that recurred as a solitary high-grade Ta with a concomitant
small focus of CIS after adequate exposure to BCG (six plus
three instillations) and during maintenance BCG (Fig. 1) [1].
According to the most existing guidelines (including
2017 European Association of Urology [EAU] guidelines
[2,3]), this clinical scenario is a condition that is best
treated with radical surgery. This also fits the recent
definition of BCG-unresponsive disease by the Food and
Drug Administration (FDA) [4] and the International
Bladder Cancer Group (IBCG) [1]. For discussion purposes,
according to an international consensus on staging of T1
disease [5], this case, where NMIBC presents as a lower-
stage disease after an initial partial response, can also be
called BCG resistant.
The currently available conservative therapies (immu-
notherapies, chemotherapies, device-assisted therapies, or
combinations) must be considered oncologically inferior to
radical surgery, since they are associated with a significant
risk of disease progression. As such, they are recommended
only in patients unfit for or who refuse radical surgeryFig. 1 – Definition of BCG-unresponsive NMIBC. BCG = bacille Calmette-Guérin; 
NMIBC = non-muscle-invasive bladder cancer.
Adapted from Kamat et al. [1].[2,3]. In this case, the patient was apparently young and fit,
and not unusually, such patients are asking their clinician to
help them weigh the “oncological benefit” versus potential
detriments of the possible treatment alternatives.
2.1. Can the prognosis of this patient be determined?
A patient such as this is usually considered at a high risk of
disease progression, but can the magnitude of this risk be
estimated in this individual patient? Both European
Organisation for Research and Treatment of Cancer EORTC
[6] and CUETO [7] risk tables work for predicting progres-
sion in individual patients with primary or recurrent NMIBC
receiving predominantly chemotherapy (EORTC) or BCG
(CUETO), respectively, but neither risk calculator applies to
a BCG-unresponsive disease.
The risk of a missed muscle-invasive bladder cancer
(MIBC) would be low in this patient, since the high risk of
discovering MIBC in T1G3 undergoing radical cystectomy
(up to 50% in the series of Fritsche et al. [8]) does not apply
to this scenario due to recurrence with Ta disease. In 87 Ta
high-grade NMIBC cases undergoing repeat transurethral
resection (TUR), the rate of persistent disease was 41%, but
none had MIBC [9].
In addition, this patient received a good quality
photodynamic diagnosis-guided TUR; this method was
recently found to significantly reduce the recurrence rate
over good-quality white-light TUR, and the effect was even
more marked in high-risk disease [10].
The SWOG trial [11] randomized patients at a high risk of
progression to receive BCG with or without maintenance.
Patients failing to achieve a complete response (CR) to BCG
had a significantly higher risk of 5-yr death compared withHG = high grade; iBCG = intravesical BCG; mBCG = maintenance BCG;
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increased risk of death). This study confirms the higher risk
of cancer-specific death for BCG-failure disease and
supports the need for an effective early treatment for this
clinical condition.
2.2. Is early cystectomy the best available treatment for high-
risk BCG-unresponsive NMIBC?
No randomized study has specifically addressed this
question. In a retrospective series of T1G3 patients,
Hautmann et al. [12] compared the results of immediate
cystectomy in 175 BCG-naïve patients versus delayed
cystectomy in 99 BCG-failure patients, and showed a 9%
5-yr cancer-specific survival (CSS) advantage in favor of
immediate cystectomy. While the delayed cystectomy arm
of this study provides a good estimate of the outcomes of
BCG failures receiving delayed surgery (75% at 5 yr and 64%
at 10 yr), it does not demonstrate that this is an ideally
effective treatment. Notably, CSS continues to decrease
beyond 5 yr from cystectomy, suggesting that cystectomy is
far from an ideal treatment.
2.3. Are current conservative therapies inferior to cystectomy?
Chemohyperthermia with mitomycin C using a radio-
frequency-emitting catheter has been tested in retrospec-
tive series and also in one small randomized controlled trial
(RCT) for BCG-failure NMIBC. In a review of 111 patients
with BCG failure, Nativ et al. [13] reported a recurrence-free
rate of 85% at 1 yr and 56% at 2 yr, with an average time to
recurrence of 16 mo. Progression rate at a median follow-up
of 16 mo was only 3%.
Initial reports of intravesical gemcitabine in NMIBC
showed promise in both BCG-naive and BCG-failure
patients. In the only RCT published so far [14], high-risk
BCG-failure NMIBC patients had a recurrence rate of 52.5%
(21/40) following intravesical gemcitabine, compared with
87.5% (35/40) for rechallenge with intravesical BCG.
Progression rates were similar between groups: gemcita-
bine 33% and BCG 37.5% (p = 0.12) [14]. Notably, the patients
were not true BCG unresponsive according to the new
definitions.
Taxanes are another group of systemically administered
chemotherapies that have been tested after failure of BCG; a
few small studies, mainly using docetaxel, have failed to
report significant results: recurrence rates up to 70% after an
average initial complete response rate (CRR) of 50% at 6 wk to
43 mo of follow-up were reported. Notably, when a progres-
sion rate was reported, it was relatively low (5%) [15].
More recent studies have combined intravesical chemo-
therapy with improved results far superior to anything we
have seen to date [16]. However, large-scale studies have
not been conducted.
In conclusion, while the oncological efficacy of these
second-line therapies remains limited in terms of response
rate and durability of response, the progression rate (with
the exception of one study) at an average follow-up of 2 yr is
usually low (5%). This suggests that there may be a 2-yrperiod during which conservative therapies can safely be
attempted in BCG-failure disease, since the majority of
patients will recur without progression, thus leaving a good
opportunity for delayed cystectomy still to be effective.
However, it must be noted that these have not been tested in
a true BCG-unresponsive patient to date.
2.4. Investigational immunological drugs (checkpoint
inhibitors): a new avenue in BCG-unresponsive disease?
The undisputed efficacy of BCG in primary high-risk NMIBC
makes the search for alternative immunotherapeutic routes
in patients who are BCG nonresponsive attractive. Rechal-
lenges with combinations of traditional immunotherapies
(BCG + interferon) have shown an acceptable initial re-
sponse rate (50%), but raise concerns in terms of durability
of response [17].
Molecules that act as PD-1 and PD-L1 inhibitors have
shown 26% objective responses in metastatic bladder cancer
with a good tolerability profile [18]. These drugs may
represent a promising avenue in BCG failures; clinical trials
investigating the role of pembrolizumab (two trials
addressing response rate and maximal tolerated dose),
atezolizumab (one trial addressing cancer response rate),
and durvalumab (one trial addressing safety) in BCG-
unresponsive disease are underway. In early reports [19], a
single agent pembrolizumab demonstrated 38% initial CRRs
in patients with BCG-unresponsive CIS.
3. Option B: Radical cystectomy in high-risk BCG-
unresponsive NMIBC
Currently, the best approach to BCG response failure in the
treatment of high-grade NMIBC is to differentiate patients
according to risk category, time of relapse, and the type of
BCG course (ie, with or without BCG maintenance) [20].
According to the recent EAU guideline update [2,3],
patients with high-grade NMIBC at 3 mo or with CIS present
at 3 and 6 mo after at least a complete induction course of
BCG are considered to be the group with the worst
prognosis among BCG failures. As noted earlier, when a
patient has persistent or recurrent disease according to the
BCG-unresponsive definition, this confers the highest risk to
the patient.
The best treatment options for this very-high-risk group
represent a challenge. As a recent review reminds [21],
since no established and effective intravesical therapies
are available for tumors that recur after BCG, radical
cystectomy remains the standard treatment for patients
who are truly unresponsive to BCG. According to the EAU
guidelines [2,3], conservative treatment alternatives are
“oncologically inferior” to radical cystectomy, since BCG
failures are unlikely to respond to further BCG therapy. In
only a few selected cases (eg, low-grade recurrent tumors),
bladder preservation strategies (immunotherapy, comput-
ed tomography, and device-assisted therapies) can be
considered acceptable; current evidence is that the
oncological safety of any other conservative treatment is
at best debatable [22].
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Patients who failed to respond to the first BCG course have a
very high risk of progression to muscle-invasive disease
(MIBC) with a subsequent fatal outcome. In 2004, Schrier
et al. [23] reported 3-yr CSS of 35% in patients who progress
to MIBC after NMIBC, compared with 67% in patients with
primary NMIBC. These results highlight the importance of
evaluating BCG-failure patients carefully, since a delayed
cystectomy may lead to worsening of survival.
A randomized clinical trial [10] in 2009 confirmed a
better prognosis for patients with primary tumors at
baseline. The population was divided into four groups
according to age, presence or absence of a CR to BCG, and
administration or not of prior intravesical therapy for
patients without a CR. The no-CR groups had a risk of death
from bladder cancer that was three to five times the risk in
younger CR patients. Moreover, among the no-CR patients,
those with a history of repeated intravesical treatments had
a higher risk of a worsening prognosis (83% vs 63% for
patients without repeat treatments and 33% for those with a
CR).
Support for bladder-sparing treatment has been
reported by a retrospective comparison of recurrent
NMIBC patients who were treated with radical cystectomy
or additional intravesical therapies [24]. A delayed
cystectomy in this population seemed not to affect the
mortality rate, with no statistically significant differences
in the 5-yr CSS. However, this study may have been
affected by a number of selection biases, since no
information was reported regarding pathological charac-
teristics at the first diagnosis or type of subsequent
recurrences. Most of the patients treated with radical
cystectomy at the first recurrence had a higher incidence of
T1 disease confirmed by precystectomy pathological TUR
specimens. In the face of the missing information, it is
possible that patients treated with an early cystectomy
may have had a more aggressive primary tumor.
In 2010, Tilki et al. [25] tried to address the prognostic
value of CIS refractory to intravesical therapy. Surprisingly,
BCG-refractory CIS was upstaged upon inspection of the
radical cystectomy specimens in >50% of the cases;
approximately 25% revealed MIBC and 5.8% of the patients
had metastases to regional lymph nodes. CSS in this group
of patients was 85%; lymph-node density metastases and
lymphatic vessel invasion were identified as the most
important predictors of mortality.
Further support for the importance of performing radical
cystectomy to prevent progression to MIBC in high-risk
NMIBC was provided by a retrospective study published in
2005 [26]. Of 62 BCG-failure patients treated with cystec-
tomy, the 5-yr CSS reached 90% in those who were not
upstaged at cystectomy.
3.2. Are there any circumstances when delay of cystectomy is
correct?
There are patients who experience recurrence of low-grade
tumors after being treated for high-grade NMIBC. Thesepatients do well and the risk of progression is really low, so
another conservative approach might be offered [27].
It is known also that in surgically high-risk patients with
comorbidities, the possibility of complications and the risk
of dying in the postoperative period are increased. Clearly,
the pros and cons of going ahead with radical surgery must
be carefully explained to and evaluated with the patient
[28].
If the patient is worried about the short- and long-term
sequelae and possible impairment of the quality of life,
other treatments can be considered or the patient can be
entered into a clinical trial.
4. Discussion of treatment options
BCG-unresponsive disease is an NMIBC category at a very
high risk of progression and consequently of cancer-related
adverse events, including death. The US FDA defines BCG-
unresponsive disease as follows: “Persistent high-grade
disease or recurrence within 6 mo (or 12 mo for CIS) of
receiving at least two courses of intravesical BCG (at least
five of six induction doses and at least two of three
maintenance doses); or T1 high-grade disease at the first
evaluation following induction BCG alone (at least five of six
induction doses).” Based on the available data, current
guidelines from the EAU, American Urological Association,
IBCG, and other agencies recommend a radical cystectomy.
This is because not only does the “gold standard” of radical
surgery offer the best chance of CSS, but importantly,
delaying extirpative surgery can mean that the window of
opportunity for curing the disease gets lost.
Second-line conservative therapies have so far been
disappointing in terms of both initial response rates and 1-
and 2-yr recurrences. That being said, most of the available
studies report low rates (5%) of progression at 2 yr, leaving a
decent window of opportunity for assessing new conserva-
tive strategies in an informed patient. Hence, regulatory
bodies have allowed single-arm studies in patients who
refuse or are not eligible for radical cystectomy. Based on
this, several trials have emerged in this area of BCG-
unresponsive disease; these are summarized in the study by
Li et al. [16].
Clearly, while the US FDA’s guidelines will improve the
quality of trial design, many cystectomy-ineligible patients
with BCG-unresponsive disease today are unwilling to
participate in these ongoing trials. For these patients,
alternative intravesical agents need to be considered.
Unfortunately, valrubicin, which is the only agent approved
for recurrent CIS after intravesical BCG treatment, has a
dismal 8% CRR at 30-mo follow-up [29]. Alternative options
with higher response rates include other intravesical
chemotherapies, including gemcitabine, docetaxel, and
sequential or combination therapy; for example: combina-
tion treatment with gemcitabine and docetaxel has yielded
1- and 2-yr CRRs of 49–54% and 34%, respectively [30]. Of
course, when data finally emerge from ongoing trials of
checkpoint inhibitors and chemohyperthermia, as well as
gene therapy and antibody-drug conjugates, more options
will be available for our patients.
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Patients with BCG-unresponsive disease are extremely
unlikely to benefit from further therapy with BCG and
represent a unique population for study of new therapies.
For the current patient, we must recognize this and
encourage him to participate in a clinical trial unless he
agrees to undergo a radical cystectomy, which must be
offered, as it is the only treatment to date that has proven
effects on reducing the risk of progression and death after
failure of BCG. However, if he refuses a radical cystectomy
and is not able to participate in clinical trials, then the
currently available data would support the use of combina-
tion chemotherapy or chemohyperthermia in this patient.
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